Conexiant’s news site is now MDSpire News. Learn more
Advertisement
This Week’s CGT News: Bristol Myers Ends Cellares Manufacturing Agreement
A first-in-human study reduces stem-cell collection and manufacturing times, Bristol Myers ends its Breyanzi agreement with Cellares, and two approaches strengthen CAR T-cell activity against solid tumors
Bristol Myers Squibb has terminated its partnership with Cellares for the manufacturing of CAR T-cell therapy Breyanzi, citing that Cellares’ Cell Shuttle platform did not meet the necessary requirements. This decision will lead to approximately 100 job cuts at Cellares’ facility in South San Francisco.
Background
The partnership between Bristol Myers Squibb and Cellares was established to enhance the commercial-scale manufacturing of Breyanzi, a CAR T-cell therapy indicated for certain types of lymphoma. The termination of this agreement raises questions regarding the manufacturing capabilities for CAR T therapies.
Data Highlights
No numerical data or trial data were provided in the source material.
Key Findings
Bristol Myers Squibb ended its manufacturing agreement with Cellares for Breyanzi.
The agreement was valued at up to $380 million and included manufacturing capacity in the US, EU, and Japan.
Cellares disputes Bristol Myers' assessment of its Cell Shuttle platform's capabilities.
The termination will result in approximately 100 job cuts at Cellares.
Breyanzi is a CD19-directed autologous CAR T-cell therapy with specific FDA indications.
Clinical Implications
The end of this partnership may impact the availability of Breyanzi for patients requiring CAR T-cell therapy.
Conclusion
The termination of the partnership between Bristol Myers Squibb and Cellares highlights the complexities involved in manufacturing standards for CAR T-cell therapies.
Ocular tumor coding can be challenging because ocular oncology often involves evolving lesions, diagnostic uncertainty, and terminology that does not always translate cleanly into ICD-10-CM codes. Understanding how to distinguish benign, malignant, in situ, and uncertain histologic behavior neoplasms is essential for accurate coding, medical necessity, and audit defensibility.
